Showing results (131-140 of 172) with videos related to
Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|March 8, 2006
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)R E Coleman, L Biganzoli, P Canney, et al.European Journal of Cancer (Oxford, England : 1990)|December 2, 2004
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group studyF Duffaud, M Borner, P Chollet, et al.Breast (Edinburgh, Scotland)|October 19, 2005
Neoadjuvant endocrine therapy in breast cancerC Abrial, M-A Mouret-Reynier, H Curé, et al.Revue Des Maladies Respiratoires|June 1, 1997
[Role of nocturnal oximetry in screening for sleep apnea syndrome in pulmonary medicine. Study of 329 patients]L Lacassagne, A Didier, M Murris-Espin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acidD Machover, E Goldschmidt, P Chollet, et al.American Journal of Clinical Oncology|June 1, 1997
Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year resultsJ P Ferrière, S Charrier, H Curé, et al.Journal of Neuro-Oncology|April 1, 2006
Cystemustine in recurrent high grade gliomaX Durando, E Thivat, H Roché, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classesF-C Bidard, M-C Matthieu, P Chollet, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Neoadjuvant chemotherapy in 126 operable breast cancersE Bélembaogo, V Feillel, P Chollet, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2006
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trialH Roché, P Kerbrat, J Bonneterre, et al.Pageof 18